Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors
Among 11 patients with relapsed or refractory CD19-positive cancers, a majority had a response to treatment with CAR-NK cells without the development of major toxic effects. (Fu...